Lv1
40 积分 2023-10-23 加入
Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer
1个月前
已完结
Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer
1个月前
已完结
A New Standard in Muscle-Invasive Bladder Cancer - The End of the Cisplatin Era?
1个月前
已完结
Neoadjuvant tislelizumab plus chemotherapy in locally advanced oral and oropharyngeal squamous cell carcinoma: A single-arm phase II clinical trial
3个月前
已完结
Pathologic Response and Survival After Neoadjuvant Immunotherapy for Resectable Mucosal HNSCC
4个月前
已关闭
Botulinum Toxin for Refractory Digital Ischemia and Ulcers in Systemic Sclerosis
4个月前
已完结
Botulinum Toxin for Refractory Digital Ischemia and Ulcers in Systemic Sclerosis
4个月前
已关闭
Botulinum Toxin for Refractory Digital Ischemia and Ulcers in Systemic Sclerosis
4个月前
已关闭
Impact of Time to Treatment Initiation in Patients with Human Papillomavirus-positive and -negative Oropharyngeal Squamous Cell Carcinoma
4个月前
已关闭
Derivation and validation of the AJCC9V pathological stage classification for HPV-positive oropharyngeal carcinoma: a multicentre registry analysis
4个月前
已完结
皖公网安备34019202002308
